M.D., Professor of Medicine, Pharmacology, Pathology, Microbiology and Immunology, Vanderbilt University
Biography
At Vanderbilt University Medical Center Dr. Elizabeth Phillips lab studies the development of genetic, molecular and cellular signals to predict and prevent severe life-threatening adverse drug reactions using novel single cell technologies and mass cytometry. She is the John A. Oates Chair in Clinical Research and Director of Personalized Immunology in the Center for Drug Safety and Immunology. She is a physician scientist clinically trained in Infectious diseases and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems. Amongst her greatest translational accomplishments between 2002-2008 she led the development of the HLA-B*57:01 genetic predictor for abacavir hypersensitivity from its discovery through implementation. Important work accomplished since the implementation of HLA-B*57:01 testing has been in elucidating the specific immunopathogenesis of abacavir hypersensitivity and other immunology-mediated drug hypersensitivity syndromes and new genetic discoveries such HLA-A*32:01 and vancomycin-induced drug reaction and eosinophilia and systemic symptoms.
Talk
Using Precision Medicine To Prevent And Understand Severe Immune-Mediated Drug Reactions
Session Abstract – PMWC 2020 Silicon Valley
Track 3 - January 24 9.30 A.M.-1.45 P.M.
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. Precision Pharmacotherapy is combining genetic, environmental, lifestyle, and other unique patient or disease characteristics to guide drug selection and dosage. This session will introduce the concept and give many examples of how precision pharmacotherapy is used in specialties such as pediatrics, psychology, cardiology and oncology to guide prescribing.
